The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

Drug Target Review

FEBRUARY 28, 2024

Human γδ TCR repertoires in health and disease. gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151-183 (2005). Normality sensing licenses local T cells for innate-like tissue surveillance. References Fichtner A, Ravens S, Prinz I. Cells 9(40):800 (2020). Kalyan S, Kabelitz D.

Therapies 105

Therapies Engineering Molecular Biology Immune Response 105

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 6,7 Approximately 10% of asthma patients have severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 21, 2020

Severe asthma is a complex, heterogenous disease and many patients continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials 40

Trials Production Clinical Trials Government 40